Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

INB-100 Following HSCT Displays Long-Lasting Activity in Pretreated AML

March 12th 2025

The γδ T-cell agent INB-100 demonstrated a 100% relapse-free survival rate in patients with AML.

Cema-Cel Induces CRs and Has Manageable Safety Profile in CD19 CAR T-Cell Therapy–Naive R/R LBCL

March 11th 2025

Cema-cel generated CRs, most of which were durable, among patients with relapsed/refractory LBCL who were naive to anti-CD19 CAR T-cell therapy.

Dr Davila on ​the Clinical Implications of Tumor Driver and Immune Escape Research in LBCL

March 10th 2025

Marco Davila, MD, PhD, discusses research investigating ways to combat immune escape mechanisms in LBCL treated with CD19-directed CAR T-cell therapy.

Five Under 5: Top Oncology Videos for the Week of 3/2

March 9th 2025

The top 5 OncLive videos of the week cover insights in TGCT, NSCLC, TNBC, AML, and MDS.

Olverembatinib Plus Chemo Receives Breakthrough Therapy Designation in China for Newly Diagnosed Ph+ ALL

March 6th 2025

First-line olverembatinib plus low-intensity chemotherapy has received breakthrough therapy designation in China for patients with Ph-positive ALL.

Dr Podoltsev on Blinatumomab Plus Consolidation Chemotherapy in Older BCR-ABL1–Negative ALL

March 4th 2025

Nikolai Podoltsev, MD, PhD, discusses the addition of blinatumomab to consolidation chemotherapy in older patients with newly diagnosed BCR-ABL1–negative ALL.

Ivosidenib/CPX-351 Shows Early Activity and Is Safe in IDH1-Mutated R/R AML, High-Risk MDS

March 4th 2025

Treatment with ivosidenib plus CPX-351 showed early efficacy in patients with relapsed/refractory AML or high-risk MDS harboring an IDH1 mutation.

Five Under 5: Top Oncology Videos for the Week of 2/23

March 2nd 2025

The top 5 videos of the week cover insights in ovarian cancer, NSCLC, CSCC, follicular lymphoma, and CLL.

The OncFive: Top Oncology Articles for the Week of 2/23

March 1st 2025

Perioperative pembrolizumab sBLA gets priority review in HNSCC, nivolumab/ipilimumab sBLA in MSI-H/dMMR CRC is under review, and more from OncLive this week.

OncLive’s FDA Approval Report: The Regulatory Rundown for February 2025

March 1st 2025

Here is your snapshot for all therapeutic options that were approved by the FDA in February 2025 spanning tumor types.

Dr Shah on the Rationale for Evaluating Zamto-Cel in R/R DLBCL

March 1st 2025

Nirav N. Shah, MD, discusses how zamto-cel might address resistance to prior CD19-directed therapy in patients with relapsed/refractory DLBCL.

CHMP Recommends Approval of Glofitamab Plus Chemotherapy for R/R DLBCL

February 28th 2025

CHMP has recommended glofitamab plus gemcitabine and oxaliplatin for R/R DLBCL.

Targeting Menin: A New Frontier in Treating Refractory Leukemias

February 28th 2025

Incorporation of menin inhibitors is central to improving the outcome of difficult-to-treat leukemias.

Dr Kitko on Clinical Outcomes With Axatilimab According to Prior Lines of Therapy for Chronic GVHD

February 27th 2025

Carrie L. Kitko, MD, discusses outcomes with axatilimab in patients with chronic graft-vs-host-disease according to prior lines of therapy received.

Dr Riedell on the Rationale for Evaluating Rapcabtagene Autoleucel in R/R DLBCL

February 27th 2025

Peter Riedell, MD, highlights the rationale for investigating CAR T-cell therapy rapcabtagene autoleucel in relapsed/refractory DLBCL.

Escalating Lymphodepletion ± Rituximab Before CD19-Directed CAR T-Cell Therapy is Safe in R/R DLBCL

February 27th 2025

Escalating doses of lymphodepleting chemotherapy with or without rituximab prior to CAR T-cell therapy was safe in relapsed/refractory DLBCL.

FDA Accepts Resubmission of BLA for Odronextamab in R/R Follicular Lymphoma

February 26th 2025

The resubmission of a BLA for odronextamab was accepted by the FDA for the treatment of patients with relapsed/refractory follicular lymphoma.

AUTX-703 Receives FDA Fast Track Designation in Relapsed/Refractory AML

February 24th 2025

The FDA has granted the novel, oral KAT2A/B degrader AUTX-703 fast track designation for the treatment of patients with relapsed/refractory AML.

Five Under 5: Top Oncology Videos for the Week of 2/16

February 23rd 2025

The top 5 videos of the week cover insights in prostate cancer, multiple myeloma, RCC, urothelial carcinoma, and LBCL.

Odronextamab Shows Efficacy, Safety in R/R DLBCL After Progression Post–CAR T-Cell Therapy

February 21st 2025

Odronextamab produced durable responses in relapsed/refractory diffuse large B-cell lymphoma after disease progression following CAR T-cell therapy.

NEXT PAGE
PREVIOUS PAGE
x